Company intelligence / Profile preview

MEPSGEN

Songpa-gu, Seoul, South Koreamepsgen.com ↗

Ownership: Private
Development stage: Preclinical

Overview

MEPSGEN develops automated organ-on-a-chip platforms that streamline cell culture and tissue simulation processes, enabling more efficient preclinical drug testing. Its ProMEPS™ system automates previously manual steps in MPS modeling. The company has demonstrated non-clinical efficacy of its nanomedicine candidate MG-GHC24 in patient-derived glioblastoma tissues and plans to launch a GMP-grade NanoCalibur device in 2025 while advancing its own therapeutic pipeline toward clinical trials.

Therapeutic areas: OncologyOther
Modalities: NanomedicinemRNA therapeuticsAntisense oligonucleotides (ASOs)
Industry: Biotech

Drug pipeline

4 assets

MG-GDX19

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

ChaBio HospitalK-BIO HealthCellartgenCorestem ChemonWoojung BioGeorgia Tech

Beyond the preview

Go deeper on MEPSGEN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEPSGEN.

Explore the full profile